Hansa Biopharma interim report January – March 2022
· Solid sales growth in Q1 2022 · Market access secured in Germany and in France · Marketing authorization granted in Israel · Results from Phase 2 program in anti-GBM published in Journal of American Society of Nephrology (JASN)Lund, Sweden April 21, 2022 Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to March 2022. Highlights for the first quarter 2022 · Solid sales growth in the first quarter with SEK 24.2m in product sales; total revenue amounted to SEK